AA
ACRS icon

AlphaCentric Advisors’s Aclaris Therapeutics ACRS Stock Holding History

AlphaCentric Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$989K Buy
68,000
+17,000
+33% +$258K 0.29% 32
2021
Q3 		$918K Buy
51,000
+14,000
+38% +$224K 0.23% 36
2021
Q2 		$650K Buy
+37,000
New +$840K 0.18% 47

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AlphaCentric Advisors's ACRS Position: Q4 2021 in Review

AlphaCentric Advisors increased its Aclaris Therapeutics (ACRS) stake by 33% in Q4 2021, buying an estimated $258K and bringing the position to 68,000 shares worth $989K. The position accounts for 0.29% of the portfolio, ranked #32.

AlphaCentric Advisors first reported a position in ACRS in Q2 2021 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • AlphaCentric Advisors held 68,000 shares of Aclaris Therapeutics worth $989K as of Q4 2021.
  • AlphaCentric Advisors bought 17,000 Aclaris Therapeutics shares in Q4 2021, an estimated $258K.
  • Aclaris Therapeutics made up 0.29% of AlphaCentric Advisors's portfolio in Q4 2021, its #32 holding.
  • AlphaCentric Advisors first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.